BOCH
Blue Owl Capital Holdings Portfolio holdings
AUM
$310M
This Quarter Return
+13.87%
1 Year Return
+6.98%
3 Year Return
+59.66%
5 Year Return
–
10 Year Return
–
AUM
$516M
AUM Growth
+$516M
(+43%)
Cap. Flow
+$121M
Cap. Flow
% of AUM
23.43%
Top 10 Holdings %
Top 10 Hldgs %
65.39%
Holding
139
New
98
Increased
11
Reduced
9
Closed
3
Top Buys
| 1 |
Nuveen Churchill Direct Lending
NCDL
|
$70.4M |
| 2 |
ProShares UltraPro QQQ
TQQQ
|
$23.6M |
| 3 |
Conduent
CNDT
|
$13.6M |
| 4 |
Holley
HLLY
|
$7.5M |
| 5 |
LanzaTech
LNZA
|
$5.59M |
Top Sells
| 1 |
Toast
TOST
|
$8.31M |
| 2 |
Ultragenyx Pharmaceutical
RARE
|
$5.83M |
| 3 |
Viking Therapeutics
VKTX
|
$5.04M |
| 4 |
Tourmaline Bio
TRML
|
$4.76M |
| 5 |
Mineralys Therapeutics
MLYS
|
$3.08M |
Sector Composition
| 1 | Healthcare | 53.49% |
| 2 | Financials | 20.14% |
| 3 | Technology | 17.55% |
| 4 | Consumer Discretionary | 1.46% |
| 5 | Industrials | 1.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Nuveen Churchill Direct Lending
NCDL
$789M
| $70.4M | 13.57% | +4,039,553 | New | +$70.4M |
|
2
Klaviyo
KVYO
$9.73B
| $42.4M | 8.18% | 1,198,270 | – | – |
|
|
3
Tourmaline Bio
TRML
$601M
| $39.3M | 7.59% | 1,530,401 -185,000 | -11% | -$4.76M |
|
4
Pliant Therapeutics
PLRX
$101M
| $33.7M | 6.5% | 3,004,199 | – | – |
|
5
Cullinan Oncology
CGEM
$445M
| $33.7M | 6.49% | 2,010,972 -38,200 | -2% | -$639K |
|
6
Blue Owl Capital
OBDC
$7.33B
| $29.8M | 5.75% | 2,045,070 | – | – |
|
7
Larimar Therapeutics
LRMR
$310M
| $27.3M | 5.26% | 4,166,829 +307,361 | +8% | +$2.01M |
|
|
8
ProShares UltraPro QQQ
TQQQ
$26B
| $23.6M | 4.54% | +325,000 | New | +$23.6M |
|
9
enGene Holdings
ENGN
$236M
| $20.2M | 3.89% | 3,058,969 +609,142 | +25% | +$4.02M |
|
10
EverCommerce
EVCM
$2.09B
| $17M | 3.28% | 1,641,929 | – | – |
|
|
SLRN
11
DELISTED
ACELYRIN
SLRN
| $13.8M | 2.66% | 2,793,946 -132,082 | -5% | -$651K |
|
|
12
Conduent
CNDT
$439M
| $13.6M | 2.61% | +3,363,022 | New | +$13.6M |
|
13
Repare Therapeutics
RPTX
$71.7M
| $11.6M | 2.24% | 3,372,499 | – | – |
|
14
Context Therapeutics
CNTX
$75.4M
| $10.6M | 2.05% | 5,411,290 +250,000 | +5% | +$490K |
|
|
15
Ultragenyx Pharmaceutical
RARE
$2.89B
| $9.07M | 1.75% | 163,238 -105,000 | -39% | -$5.83M |
|
16
Disc Medicine
IRON
$2.07B
| $8.61M | 1.66% | 175,260 -40,000 | -19% | -$1.97M |
|
|
17
Holley
HLLY
$490M
| $7.5M | 1.45% | +2,543,588 | New | +$7.5M |
|
|
ETWO
18
DELISTED
E2open Parent Holdings
ETWO
| $7.28M | 1.4% | 1,650,943 | – | – |
|
19
Keros Therapeutics
KROS
$618M
| $7.12M | 1.37% | 122,633 -35,000 | -22% | -$2.03M |
|
|
IMA
20
ImageneBio, Inc. Common Stock
IMA
$150M
| $7.08M | 1.37% | 4,091,118 | – | – |
|
21
Aquestive Therapeutics
AQST
$456M
| $6.1M | 1.18% | 1,225,000 +85,000 | +7% | +$423K |
|
|
INZY
22
DELISTED
Inozyme Pharma
INZY
| $5.86M | 1.13% | 1,120,027 | – | – |
|
|
23
LanzaTech
LNZA
$49.1M
| $5.59M | 1.08% | +2,926,514 | New | +$5.59M |
|
24
Compass Therapeutics
CMPX
$483M
| $5.3M | 1.02% | 2,879,712 +50,000 | +2% | +$92K |
|
25
CCC Intelligent Solutions
CCCS
$6.45B
| $5.05M | 0.97% | +457,104 | New | +$5.05M |
|